LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients

HØRSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (CSE:LCP) today announced positive results from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf®, by maintaining

Back to news